Study 767905/008 Extension Study: Alvimopan for Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects

Phase 2

Completed

• Conditions: Cancer; Bowel Dysfunction
• Interventions: Drug: alvimopan; Drug: placebo

• Registration Number: NCT00135577
• Lead Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Brief Summary

Study SB-767905/008 was a multicenter study to evaluate the effectiveness and safety of multiple dosage regimens of an investigational drug for the treatment of constipation due to prescription pain medication in participants with cancer pain.

Study ABD101684 will serve as an extension to Study SB-767905/008 and offer continued access to blinded investigational product to participants who have completed the original study. The purpose of Study ABD101684 is to evaluate the safety and efficacy of alvimopan compared to placebo in subjects who completed Study SB-767905/008 and elected to participate in this extension study.

Detailed Description

Not available

Study Timeline

• Study Start: 2004-09
• Study First Submitted: 2005-08-24
• Study First Submitted QC: 2005-08-24
• Study First Posted: 2005-08-26
• Primary Completion: 2007-04
• Study Completion: 2007-04
• Status Verified: 2009-09
• Last Update Submitted: 2015-09-01
• Last Update Posted: 2015-09-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 67

Inclusion Criteria

• Completed GSK sponsored alvimopan (opioid-induced bowel dysfunction) OBD study for subjects with cancer-related pain, e.g. SB-767905/008.
• Taking full agonist opioid therapy for cancer related pain.
• Met entry criteria of OBD in original study and per investigator continues to require therapy for management of OBD.
• Capable of completing paper questionnaires at the study visits.

Read More

Exclusion Criteria

• Unable to eat or drink.
• Taking opioids for management of drug addiction.
• Unable to use only rescue laxatives provided.
• Inappropriately managed severe constipation that puts subject at risk of complications.
• Has gastrointestinal (GI) or pelvic disorder known to affect bowel transit.
• Concomitant medication(s), medical condition, or clinically significant laboratory abnormality that could jeopardize subject and also contraindicate study participation.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Alvimopan 1 mg Once Daily (QD)	placebo	Participants who did not have an interruption in blinded investigational product between the original study and the extension study received Alvimopan 1 mg in the morning and received placebo in the evening. Participants who had an interruption in blinded investigational product between studies received 0.5 mg of alvimopan in the morning and placebo in the evening for 3 days, then 1 mg of alvimopan in the morning and placebo in the evening for the remaining 3 weeks.
Placebo	placebo	Placebo was administered orally once in the morning and once in evening.
Alvimopan 0.5 mg Twice Daily (BID)	alvimopan	0.5 milligrams (mg) of alvimopan was administered orally once in the morning and once in the evening.
Alvimopan 1 mg Once Daily (QD)	alvimopan	Participants who did not have an interruption in blinded investigational product between the original study and the extension study received Alvimopan 1 mg in the morning and received placebo in the evening. Participants who had an interruption in blinded investigational product between studies received 0.5 mg of alvimopan in the morning and placebo in the evening for 3 days, then 1 mg of alvimopan in the morning and placebo in the evening for the remaining 3 weeks.
Alvimopan 1 mg Twice Daily (BID)	alvimopan	Participants who did not have an interruption in blinded investigational product between the original study and the extension study received Alvimopan 1 mg once in the morning and once in the evening. Participants who had an interruption in blinded investigational product between studies received 0.5 mg of alvimopan once in the morning and once in the evening for 3 days, then 1 mg of alvimopan once in the morning and once in the evening.

Primary Outcome Measures

Name	Time	Method
Incidence of reported adverse events, including serious adverse events

Secondary Outcome Measures

Name	Time	Method
Incidence of treatment-limiting toxicities, changes in pain intensity, patient satisfaction, health outcome measures

Trial Locations

Locations (1)

GSK Investigational Site; 🇬🇧 Nottingham, United Kingdom